Chimeric antigen receptor
Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises •a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: •b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.
1. A method for treating cancer which comprises the step of administering a T cell to a subject,
wherein the T cell expresses a chimeric antigen receptor (CAR) comprising
a) a disialoganglioside (GD2)-binding domain and spacer, shown as amino acids 21 to 311 of SEQ ID NO: 29,
b) a hydrophobic alpha helical transmembrane domain, and
c) a CD28-CD3Zeta endodomain shown as SEQ ID NO: 17; and
wherein the cancer is a melanoma, medulloblastoma, soft-tissue sarcoma, osteosarcoma or small-cell lung cancer.
2. The method of claim 1 wherein the cancer is a small-cell lung cancer.